c Radioimmunotherapy (RIT) takes advantage of the specificity and affinity of the antigen-antibody interaction to deliver microbicidal radioactive nuclides to a site of infection. In this study, we investigated the microbicidal properties of an alpha particleemitting 213 Bi-labeled monoclonal antibody (MAb), EA2-1 ( 213 Bi-EA2-1), that binds to the immunodominant antigen on Bacillus anthracis spores. Our results showed that dormant spores were resistant to 213 Bi-EA2-1. Significant spore killing was observed following treatment with EA2-1 labeled with 300 Ci 213 Bi; however, this effect was not dependent on the MAb. In contrast, when spores were germinating, 213 Bi-EA2-1 mediated MAb-specific killing in a dose-dependent manner. Dormant spores are very resistant to RIT, and RIT should focus on targeting vegetative cells and germinating spores.
I
n 2001, Bacillus anthracis spores were intentionally used for a terrorist attack, and the event caused widespread contamination and several deaths. Since then, many groups have investigated the ability to destroy spores with methods ranging from treatment with heat to UV radiation but with varied success (reviewed in reference 1). Consequently, there is an urgent need to develop novel approaches for sterilizing spores. Radioimmunotherapy (RIT) is a therapeutic modality that employs a microbe-specific monoclonal antibody (MAb) labeled with a radioisotope delivering lethal doses of radiation to microbial cells through various mechanisms (2) (3) (4) (5) (6) . Recently, a number of MAbs have been used in experimental RIT of infectious diseases. It has been shown to be effective against HIV infection as well as cancers associated with viral infections (7, 8) . Our group has shown that antibody (Ab)-delivered microbicidal ionizing radiation was effective against Cryptococcus neoformans and Streptococcus pneumoniae by labeling a pathogen-specific MAb with rhenium-188 ( 188 Re) and bismuth-213 ( 213 Bi) (4, 9, 10) . Furthermore, our group recently applied this technique to the treatment of experimental anthrax infection with radiolabeled MAbs that target secreted B. anthracis toxin components (11) .
B. anthracis is a Gram-positive, spore-forming, rod-shaped bacterium and the causative agent of anthrax, which usually occurs following contact with spores (12) . B. anthracis spores are a highly effective biological weapon, given their infectivity, dispersibility in the air, and resistance to heat and harsh conditions (13) . B. anthracis spores are enclosed by a prominent bipartite layer called the exosporium, which is composed of a basal layer and an external hair-like nap. The filaments of the nap are formed by trimers of a single collagen-like glycoprotein called BclA (14, 15) , which is the immunodominant antigen on the spore surface (16) . A number of anti-BclA MAbs that are highly specific and capable of distinguishing B. anthracis spores from spores produced by closely related Bacillus species have been developed (14) . In this study, we utilized an anti-BclA MAb radiolabeled with 213 Bi to investigate targeted radiation for sterilization of B. anthracis spores.
Monoclonal antibodies and B. anthracis spores. MAb EA2-1 IgG2b specific for BclA and MAb 19-3 IgG2b (isotype-matched non-spore-binding control) have been described previously (14) . Spores of B. anthracis Sterne 34F2 (pXO1 ϩ pXO2 Ϫ ) and B. anthracis Sterne ⌬bclA were prepared and purified as previously described (16) . Before each experiment, spores were washed with ice-cold water under sterile conditions to remove soluble material released by lysed cells and then collected at 10,000 ϫ g. Refractile spore rods were visualized with a 40ϫ phase objective using an Axiovert 200M inverted microscope equipped with a Hamamatsu ORCA ER cooled charge-charge-coupled-device camera (CCD) and controlled by AxioVison 4.6 software (Carl Zeiss Micro Imaging, New York, NY). Germination of spores results in a change in spore refractility that can be detected by phase-contrast microscopy (17) . Spores were also stained with malachite green and counterstained with safranin to detect germinating spores (18) . Before each experiment, we inspected the spores under phasecontrast microscope for the presence of short refractile rods. Inspection revealed that the spores were stable and did not germinate during experimental assays (Fig. 1) . Malachite green staining confirmed these results (data not shown).
Radiolabeling of MAbs with 213 Bi. 213 Bi (an alpha particle emitter) was eluted from an 225 Ac generator from the Institute for Transuranium Elements, Karlsruhe, Germany (19) . MAbs conjugated to bifunctional chelating agent N- [2- (Fig. 2B) . Our results confirm that B. anthracis spores are highly resistant to irradiation, as previously reported (21) . It is important to note that the activities of radiolabeled MAbs in our studies are well below the maximum tolerated doses of 213 Bi-labeled IgGs which were administered in mice (2) .
Susceptibility of germinating B. anthracis Sterne spores to RIT. For some experiments, B. anthracis Sterne 34F2 and ⌬bclA 34F2 spores were activated for 30 min at 65°C and then exposed to 75-and 150-Ci 213 Bi-EA2-1 or 213 Bi-19-3. The incubation of germinating spores with 213 Bi-EA2-1 resulted in an Ab-specific 40 to 50% reduction in CFU compared to the level of CFU with unlabeled MAbs. In contrast, the same activities of the control MAb resulted in much less significant killing (Fig. 3A) . The specific nature of 213 Bi-labeled MAb killing of germinating spores was confirmed when a mutant lacking BclA glycoprotein was subjected to the same doses of the BclA-specific and control antibodies and no killing was observed (Fig. 3B) .
Statistical analysis. CFU were analyzed by t test analysis (Sigmastat, Chicago, IL).
Discussion. B. anthracis spores leave the resistant, dormant state through a process of germination under the appropriate conditions (17, 21) , which makes them sensitive to environmental insults. The spores then become pathogenic and lead to the development of anthrax disease in a host, thus presenting the opportunities for the drugs to eliminate germinating spores. In fact, dividing cells are much more susceptible to radiation damage than the nondividing ones. In our study, we used RIT as a novel therapeutic FIG 2 (A) method which significantly affected the viability of germinating spores. In contrast, spores that were not germinating were not susceptible to particulate alpha radiation delivered by a MAb specific for the dominant spore surface antigen, confirming the remarkable radioresistence of the dormant B. anthracis spores. Apart from the intrinsic radioresistance of spores relative to vegetative cells, our current understanding of the pathogenesis of anthrax is that spores are rapidly ingested by macrophages and carried to lymph nodes, where they germinate (22) , occurring within 1 h in the lung (23) . In contrast, some studies reveal that dormant spores are not rapidly ingested and have been recovered from the lungs several months after infection (24) (25) (26) . Nonetheless, it is possible that insufficient radiolabeled Ab targeting spore antigens would be found in the airways at the time of infection or that it could penetrate a macrophage to target an intracellular spore. Hence, the combination of intrinsic radioresistance and the pathogenesis of infection suggests that germinating spores or vegetative bacterial cells may be better targets for RIT.
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